Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Journey Medical (DERM) Interest & Investment Income: 2022-2025

Historic Interest & Investment Income for Journey Medical (DERM) over the last 4 years, with Sep 2025 value amounting to $154,000.

  • Journey Medical's Interest & Investment Income fell 18.09% to $154,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $632,000, marking a year-over-year decrease of 6.92%. This contributed to the annual value of $757,000 for FY2024, which is 135.09% up from last year.
  • Latest data reveals that Journey Medical reported Interest & Investment Income of $154,000 as of Q3 2025, which was up 11.59% from $138,000 recorded in Q2 2025.
  • Over the past 5 years, Journey Medical's Interest & Investment Income peaked at $217,000 during Q1 2024, and registered a low of $3,000 during Q1 2022.
  • For the 3-year period, Journey Medical's Interest & Investment Income averaged around $138,182, with its median value being $149,000 (2025).
  • Its Interest & Investment Income has fluctuated over the past 5 years, first skyrocketed by 3,966.67% in 2023, then slumped by 31.34% in 2025.
  • Quarterly analysis of 4 years shows Journey Medical's Interest & Investment Income stood at $50,000 in 2022, then surged by 126.00% to $113,000 in 2023, then soared by 69.03% to $191,000 in 2024, then decreased by 18.09% to $154,000 in 2025.
  • Its Interest & Investment Income stands at $154,000 for Q3 2025, versus $138,000 for Q2 2025 and $149,000 for Q1 2025.